China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Operating Margin %: 20.78% (As of Mar. 2026) — 40% Above Median


SHSE:600062 China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
90 GF Score
Price ¥16.43
GF Value ¥18.75
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is China Resources Double-Crane Pharmaceutical Co Operating Margin %?

China Resources Double-Crane Pharmaceutical Co SHSE:600062 -0.90% 90 Operating Margin % is 20.78% as of Mar. 2026, which is 40% above its 10-year median of 14.82. GuruFocus rates SHSE:600062 with a GF Score™ of 90/100 and a GF Value™ of ¥18.75 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, China Resources Double-Crane Pharmaceutical Co ranks better than 73.22% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. China Resources Double-Crane Pharmaceutical Co's Operating Income for the three months ended in Mar. 2026 was ¥583 Mil. China Resources Double-Crane Pharmaceutical Co's Revenue for the three months ended in Mar. 2026 was ¥2,807 Mil. Therefore, China Resources Double-Crane Pharmaceutical Co's Operating Margin % for the quarter that ended in Mar. 2026 was 20.78%.

Good Sign:

China Resources Double-Crane Pharmaceutical Co Ltd operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for China Resources Double-Crane Pharmaceutical Co's Operating Margin % or its related term are showing as below:

SHSE:600062' s Operating Margin % Range Over the Past 10 Years
Min: 12.11   Med: 14.82   Max: 16.75
Current: 16.15


SHSE:600062's Operating Margin % is ranked better than
73.22% of 956 companies
in the Drug Manufacturers industry
Industry Median: 7.58 vs SHSE:600062: 16.15

China Resources Double-Crane Pharmaceutical Co's 5-Year Average Operating Margin % Growth Rate was 4.00% per year.

China Resources Double-Crane Pharmaceutical Co's Operating Income for the three months ended in Mar. 2026 was ¥583 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1,732 Mil.


China Resources Double-Crane Pharmaceutical Co  (SHSE:600062) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


China Resources Double-Crane Pharmaceutical Co Operating Margin % Related Terms


China Resources Double-Crane Pharmaceutical Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for China Resources Double-Crane Pharmaceutical Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Double-Crane Pharmaceutical Co Operating Margin % Chart

China Resources Double-Crane Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.11 13.84 15.92 15.08 16.30

China Resources Double-Crane Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.92 20.48 14.10 9.03 20.78

SHSE:600062 vs ZTS, UTHR: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Double-Crane Pharmaceutical Co Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Double-Crane Pharmaceutical Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where China Resources Double-Crane Pharmaceutical Co's Operating Margin % falls into.


SHSE:600062
90GF Score
China Resources Double-Crane Pharmaceutical Co Ltd SHSE:600062
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Resources Double-Crane Pharmaceutical Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

China Resources Double-Crane Pharmaceutical Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=1793.05 / 11000.795
=16.30 %

China Resources Double-Crane Pharmaceutical Co's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=583.262 / 2806.583
=20.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 20.78% mean?
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Operating Margin % of 20.78% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is 40% above median its historical median of 14.82. Over the past decade, China Resources Double-Crane Pharmaceutical Co's Operating Margin % has ranged from 12.11 to 16.75. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #256 out of 956 companies in the Drug Manufacturers industry, placing it in the top 26.8%.
Is China Resources Double-Crane Pharmaceutical Co's Operating Margin % too high?
China Resources Double-Crane Pharmaceutical Co's current Operating Margin % of 20.78% is 40% above median its 10-year median of 14.82. Over the past 10 years, this metric has ranged from a low of 12.11 to a high of 16.75. The Drug Manufacturers industry median Operating Margin % is 7.58. China Resources Double-Crane Pharmaceutical Co's value of 20.78% is 174.1% above this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #256 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #256 out of 956 companies for Operating Margin %. This puts China Resources Double-Crane Pharmaceutical Co in the upper half of its industry. The industry median Operating Margin % is 7.58. China Resources Double-Crane Pharmaceutical Co's value of 20.78% is 174.1% above this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own Operating Margin % has ranged from 12.11 to 16.75 over the past decade. While the company's 10-year median is 14.82 vs. the industry median of 7.58, China Resources Double-Crane Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.58, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current Operating Margin % of 20.78% is 174.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current Operating Margin % is 20.78%, which is 40% above median its own 10-year median of 14.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.75, compared to a current price of ¥16.43 — trading 12.4% below its estimated fair value. The current Operating Margin % is 20.78%, which is 40% above median its 10-year median of 14.82 and 174.1% above the Drug Manufacturers industry median of 7.58. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Operating Margin % is 20.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥16.43 is trading 12.4% below its estimated GF Value™ of ¥18.75. GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600062:

  • Operating Margin %: 20.78% (40% above median its 10-year median of 14.82)
  • GF Value™: ¥18.75 vs. price of ¥16.43 (12.4% below fair value)
  • GF Score™: 90/100 with 4 warning signs
  • Industry Position: 174.1% above the Drug Manufacturers median (#256 of 956)

No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Resources Double-Crane Pharmaceutical Co Business Description

Address No. 1, East Second Road, Lijing, Wangjing, Chaoyang District, Beijing, CHN, 100102
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score

Get the complete analysis for SHSE:600062

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.43
Price
¥18.75
GF Value